Tandem Diabetes Care, Inc.
NASDAQ:TNDMMedical - Devices
+$0.24 today
- Market cap
- $1.19B
- Beta
- 1.57
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.38
Volume 2.35M
Average 2.43M
TNDM EBITDA Margin
EBITDA as a percentage of revenue.
Tandem Diabetes Care, Inc.NASDAQ: TNDM
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -5.6%
EBITDA Margin was -5.6% in Q1 FY2026, up 44.1 pp from a year earlier. On a trailing-twelve-month basis it was -7.0%, up 6.7 pp year over year. Over 3 fiscal years it narrowed by 8.0 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 18 analysts of -0.9% for the fiscal year ending Dec 2026, up from -17.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -5.6%-9.4 pp QoQ
- Last fiscal yearDec 2025
- -17.2%-6.7 pp YoY
- LTMMar 2026
- -7.0%+6.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +44.1 pp | +15.1 pp | -29.0 pp |
| 1 year | -6.7 pp | +16.3 pp | +23.0 pp |
| 3 years | -8.0 pp | +25.1 pp | +33.0 pp |
| 5 years | +29.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -17.2%
- Year-over-year change
- -6.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -17.2% | -6.7pp |
| FY2024 | 2024-12-31 | -10.5% | +15.7pp |
| FY2023 | 2023-12-31 | -26.3% | -17.0pp |
| FY2022 | 2022-12-31 | -9.3% | -14.1pp |
| FY2021 | 2021-12-31 | 4.8% | — |
EBITDA Margin vs competitors
How TNDM compares with its peers on the latest reported figures
- TNDM's LTM Mar 2026 EBITDA Margin of -7.0% is the 5th highest of the 7 companies compared; the peer median is 6.4%.
- Its year-over-year change of +6.7 pp is the 4th highest of 6, against a peer median of +7.2 pp.
- Over three fiscal years its change of -8.0 pp compares with a peer median of +10.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 31.4% | +7.2 pp | +9.7 pp | |
| LTM Jun 2026 | 21.5% | +4.3 pp | +10.5 pp | |
| LTM Mar 2026 | 7.6% | -20.1 pp | +64.3 pp | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | 5.2% | — | +4.9 pp |
| LTM Mar 2026 | -7.0% | +6.7 pp | -8.0 pp | |
| LTM Mar 2026 | -57.6% | +41.1 pp | +35348.3 pp | |
| LTM Mar 2026 | -198.5% | +73.8 pp | -1165.0 pp | |
MMEDVMiniMed Group, Inc. | — | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding TNDM) | 6.4% | +7.2 pp | +10.1 pp | |
Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 702.8M | 801.22M | 747.72M | 940.2M | 1.01B |
| Cost of Revenue | 326.58M | 388.23M | 380.03M | 450.63M | 483.89M |
| Gross Profit | 376.22M | 412.99M | 367.69M | 489.57M | 530.85M |
| Gross Margin | 53.5% | 51.5% | 49.2% | 52.1% | 52.3% |
| Research & Development | 92.05M | 170.15M | 248.42M | 198.88M | 174.84M |
| Selling, General & Admin | 261.51M | 335.68M | 352.5M | 389.82M | 434.13M |
| Operating Expenses | 353.56M | 505.83M | 600.92M | 588.7M | 608.97M |
| Depreciation & Amortization | 13.85M | 14.33M | 15.72M | 158K | 17.67M |
| EBITDA | 34.06M | (74.21M) | (196.46M) | (99.13M) | (174.7M) |
| EBITDA Margin | 4.8% | -9.3% | -26.3% | -10.5% | -17.2% |
| Operating Income | 22.65M | (92.85M) | (233.23M) | (99.13M) | (78.12M) |
| Operating Margin | 3.2% | -11.6% | -31.2% | -10.5% | -7.7% |
| Interest Income | 674K | 6.06M | 22.86M | 17.99M | 9.09M |
| Interest Expense | 6.04M | 6.21M | 9.88M | 7.42M | 7.91M |
| Other Income / Expenses | (6.75M) | (4K) | 12.98M | 7.26M | (122.15M) |
| Income Before Tax | 15.9M | (92.85M) | (220.25M) | (91.87M) | (200.27M) |
| Pre-Tax Margin | 2.3% | -11.6% | -29.5% | -9.8% | -19.7% |
| Income Tax Expense | 335K | 1.74M | 2.36M | 4.16M | 4.44M |
| Net Income | 15.57M | (94.59M) | (222.61M) | (96.03M) | (204.71M) |
| Net Margin | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% |
| EPS (Basic) | 0.25 | (1.47) | (3.43) | (1.47) | (3.04) |
| EPS (Diluted) | 0.24 | (1.47) | (3.43) | (1.47) | (3.04) |
| Weighted Avg Shares | 63M | 64.15M | 64.9M | 65.45M | 67.29M |
| Weighted Avg Shares (Diluted) | 64.35M | 64.15M | 64.97M | 65.45M | 67.29M |
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.